Clinical Trial Search

Primary: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) — 0.19; 0.36 Grams per deciliter (g/dL)

Primary: Number of Participants With Adverse Event (AE) — 37; 12; 7 Participants

Primary: Median Progression Free Survival (PFS) — 13.8 years

Primary: Phase 1: Recommended Phase 2 Dose (RP2D) of Eribulin Mesilate in Combination With Irinotecan Hydrochloride — 1.4; 40 mg/m^2

Primary: Time From First Dose to Symptom Response — 155.1; 153.9 hours — p=0.3765

Primary: Change From Baseline in ADAS-Cog Score — 1.39; 3.26 score on a scale — p=0.125

Primary: Expired Air Carbon Monoxide (CO) to Assess Recent Smoking — 18.3; 22.9; 21.3; 25.6 Parts per million (ppm) — p=0.01

Primary: Initial Numeric Rating Scale (NRS) Pain Score Upon Arrival — 4; 4 score on a scale

Primary: Progression Free Survival (PFS) — 5.1 months

Primary: Postprandial Glucose Nadir — 57.1; 59.2; 47.1 mg/dL

Primary: Percentage of Smokers With Delivery of Brief Interventions and/or Referral to Treatment — 7; 36 Participants

Primary: Identification of Safe-dose for the Phase 2 Double-blind Phase in the Lead-in Phase — 10 milligrams (mg)

Primary: Time to First Bowel Movement After Surgery — 66.5; 68.3 hours

Primary: Response in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 - 12 Hours (AUC0-12) — 0.187; 0.117; 0.057; 0.211 Liter (L) — p=<0.0001

Primary: Overall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5 — 14.39; 11.10 Months — p=<0.0001